Physician profile
Gregory A Wallman
NPI 1043324643
$2,849.34
in general payments reported to CMS, 2019-2025
26 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $1,247 · 2022: $13.27 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $459.89 | 2019-2020 | |
| Novo Nordisk INC | $318.22 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $206.54 | 2019-2020 | |
| Amarin Pharma, INC. | $157.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $154.79 | 2019-2020 | |
| Pfizer INC. | $147.94 | 2019-2025 | |
| Lilly USA, LLC | $140.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $129.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.24 | 2019-2020 | |
| Abbvie INC. | $120.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $118.72 | 2019-2025 | Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $99.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $68.79 | 2019-2020 | |
| Sanofi Pasteur INC. | $65.40 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.78 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $62.91 | 2019 | |
| Axsome Therapeutics, INC. | $61.96 | 2025 | Symbravo |
| Amgen INC. | $54.10 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $50.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.42 | 2019 | |
| Esperion Therapeutics, INC. | $42.20 | 2020 | |
| Astellas Pharma US INC | $34.99 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $31.22 | 2019 | |
| Horizon Therapeutics Plc | $26.13 | 2019 | |
| Seqirus USA INC | $16.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wallman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.